Background
The occurrence of human B cell lymphomas is much more frequent than that of T cell lymphomas [
1]. This phenomenon might be attributed to the multiple mechanisms functioning in B lymphocytes that intrinsically generate DNA double-stranded breaks (DSBs) or mutations [
2,
3]. Developing B cells in the bone marrow (BM) undergo V(D)J recombination to assemble the variable (V) region exons of
Ig genes [
4,
5]. V(D)J recombination involves a cut-and-join mechanism initiated by the lymphocyte-specific RAG1/2 endonucleases that recognize and introduce DSBs at recombination signal sequences (RSS) flanking germline V, D, and J segments [
6]. Subsequently, broken V, D, and J segments are joined by ubiquitous non-homologous end-joining (NHEJ) [
7]. Ongoing RAG-expression in newly generated B cells allows secondary V(D)J recombination, termed “receptor editing”, a process in which additional
Ig gene rearrangements may occur in BM immature B cells [
8‐
12]. Ultimately, RAG down-regulation in mature B cells prohibits further V(D)J rearrangement [
13,
14]. However, our previous studies suggest that mature B cells may also undergo secondary V(D)J recombination at low frequency in an in vitro culture system [
15]. While RAG contributes to the genomic instability of developing B cells [
16‐
18], its role in mature B cell lymphomagenesis is still under debate.
Upon antigen activation, mature B cells undergo further genetic diversification processes, namely, class switch recombination (CSR) and somatic hypermutation (SHM), in specialized secondary lymphoid structures termed germinal centers (GCs) [
19‐
22]. Activation-induced deaminase (AID) initiates CSR and SHM [
23,
24], which deaminates cytosines in transcribed DNA and ultimately causes DSBs or point mutations [
25‐
28]. CSR is a region-specific deletional recombination process required for producing isotype-switched antibody such as IgG [
29]. AID-initiated DSBs occur at the switch (S) regions within the
Igh locus, which are eventually resolved as deletions
in cis on the same chromosomes, thereby causing the switch of constant regions of
Igh [
29]. SHM introduces predominantly point mutations into IgH and IgL V region exons, allowing the selection of B cell clones with increased affinity for antigen [
27]. Besides
Ig loci, AID can target non-Ig loci to induce genetic lesions, thereby posing a threat to genome stability [
30]. Consistently, the dysregulated AID activity contributes to tumorigenesis [
31,
32]. We and others have shown that AID is required for generating chromosomal breaks at the
Igh locus [
15] and the
Igh-c-myc translocations [
33].
Apart from programmed DSBs, B lymphocytes harbor general DSBs arising from genotoxic agents such as oxidative damage or DNA replication errors. To preserve genome integrity, two major DSB repair pathways operate in mammalian cells: homologous recombination (HR) and NHEJ. While HR-directed repair requires homologous templates, NHEJ can repair DSBs with little or no sequence homology [
34]. The NHEJ pathway joins programmed DSBs in lymphocytes including RAG- or AID-initiated DSBs [
35] and repairs general DSBs in all types of cells [
34]. The NHEJ pathway includes Ku70, Ku80, DNA-PKcs, XLF, Artemis, XRCC4, and DNA Ligase 4 (Lig4) [
34]. XRCC4, Lig4, and possibly XLF form a complex to catalyze the end-ligation step of NHEJ [
34,
36]. Germline deletion of NHEJ results in severe combined immune deficiency due to inability to complete V(D)J recombination [
4,
7]. Conditional deletion of
Xrcc4 or
Lig4 in peripheral B cells reduces the CSR level and causes a high level of chromosomal breaks and translocations at the
Igh locus due to inability to repair AID-initiated DSBs [
15,
37]. While defective DSB repair leads to genomic instability, cell cycle checkpoints can protect organisms from adverse downstream effects, such as transformation, by eliminating damaged cells. As DSB repair and checkpoint mechanisms complement each other, loss of both can cause dramatic predisposition to transformation in mouse lymphocytes, often leading to lymphomas due to the inappropriate repair of programmed or general DSBs [
38]. For instance, deficiency of
Xrcc4,
Lig4, and
Xrcc6 (
Ku70) in conjunction with
Trp53 deficiency causes pro-B cell lymphomas carrying co-amplified
Igh-c-myc loci [
39‐
43].
TP53 is a well-known tumor suppressor gene, which encodes p53 protein capable of responding to diverse cellular stresses by regulating the expression of its target genes, thereby inducing cell cycle arrest, apoptosis, or senescence, modulating DNA repair or metabolism and serving as the guardian of the genome [
44‐
46].
We previously showed that conditionally deleting
Xrcc4 in
Trp53-deficient peripheral B cells resulted in the development of surface Ig negative lymphomas from editing and switching B cells (termed CXP lymphomas) [
47]. Although CXP tumors have mature B cell characteristics, they appear to be very different from human mature B cell lymphomas. For instance, CXP lymphomas do not express IgH or IgL chain protein on the surface or intracellularly and show no SHM in the rearranged VDJ exon [
47]. In contrast, most of human mature B cell lymphomas are surface Ig positive except classical Hodgkin’s lymphoma and a few others [
1]. These differences suggest that the mechanism of lymphomagenesis and the developmental stage of tumor progenitors are very different between CXP and human mature B cell lymphomas. Such difference may be due to the relatively early deletion of
Xrcc4 via CD21cre. CD21 begins to be expressed between the immature and the mature B cell stages, specifically in transitional B cells [
48]. Thus, in mice performing CD21cre-mediated
Xrcc4 deletion, it is likely that some DSBs are generated before the cells are recruited into the GC reaction. In the current study, we delete
Xrcc4 and
Trp53 at a later stage of mature B cell development during the GC reaction, which leads to B cell lymphomas that possess GC B cell features and harbor frequent
Ig loci translocations, ongoing DNA damage and a high level of clonal heterogeneity.
Discussion
A high level of genomic complexity and clonal heterogeneity may contribute to relapse or therapy resistance [
54,
55]; however, key determinants regulating their generation have not been clearly addressed. In the current study, we establish a unique lymphoma model by specifically deleting
Xrcc4 and
Trp53 in the subset of B cells proposed to be prone to lymphomagenesis, namely, GC B cells [
1]. Our mutant mouse B cells spontaneously develop B cell lymphomas, and we employed multiple approaches to characterize their genomic instability. Our studies reveal several important discoveries: (1)
Ig loci translocations can be attributed to distinct mechanisms including AID- or RAG-associated DSBs in mature B cells; (2) AID-associated
Igh translocations target oncogenes such as
c-myc whereas RAG-associated translocations appear to involve random genomic loci; and (3) G1XP lymphomas harbor complicated genomes including segmental translocations, and exhibit a high level of ongoing DNA damage and clonal heterogeneity. Taken together, we propose that combined NHEJ and p53 defects may serve as an underlying mechanism for a high level of genomic complexity and clonal heterogeneity in cancers.
The NHEJ and p53 deficiency models have made significant contributions to our understanding of translocation and lymphomagenesis, more importantly, the molecular mechanism of DNA repair [
15,
37,
39‐
43,
47]. Emerging evidence suggests that defects in DSB repair can lead to oncogenic genomic instability and, in support of this notion, mutations in DNA break repair factors are implicated in a number of human tumors, including breast, colon, and lung cancers [
56]. In addition, somatic mutations in NHEJ factors have been identified in different types of human tumors including hypomorphic mutations of Artemis in EBV-associated lymphomas [
57], mutations of Lig4 or XLF associated with non-Hodgkin’s diffuse large B cell lymphoma [
58‐
60], and mutations of DNA-PKcs in glioblastoma and lung cancer [
56].
TP53 mutations were associated with human BL, its leukemic counterpart L3-type B cell acute lymphoblastic leukemia, B cell chronic lymphocytic leukemia (CLL), and, in particular, its stage of progression known as Richter’s transformation [
61]. Richter syndrome (RS) is characterized by the transformation of CLL to high-grade non-Hodgkin’s lymphoma. Consistently, a recent study by performing a comprehensive molecular characterization of 86 pathologically proven RS reveals that
TP53 disruption (47.1 %) and
c-myc abnormalities (26.2 %) were the most frequent alterations in RS [
62], both of which are present in our models. Therefore, it is likely that defects in both NHEJ and p53 or in the modulators of these pathways may contribute to the development of human lymphomas, at least, a subset of them.
Our NGS data identified
Igh translocation partners,
c-myc and
Pvt-1, which are often observed in BL and a subset of diffuse large B cell lymphomas [
51,
63‐
67]. Thus, our model might provide a unique platform to better elucidate the molecular mechanisms of translocations in B cell lymphomagenesis. Prior studies demonstrate an important role of AID in promoting translocations in B cells [
30]. We and others also prove that the NHEJ deficiency-induced
Igh locus instability [
15] or the generation of
Igh-c-myc translocation is completely dependent on AID [
68]. Consistently, we found that the majority of
Igh translocations in G1XP lymphomas probably originated from AID-initiated DSBs, further solidifying its role in inducing
Igh locus genomic instability. Furthermore, we find that half of
Ig translocations occur in close proximity to V gene segments in the
Igh,
Igκ, or
Igλ locus, strongly implicating these translocations catalyzed by RAGs. Notably, the partners of these
Ig V gene translocations are random genetic loci or intergenic regions scattered all over the genome. We suggest that the generation of such translocations probably is largely influenced by mechanistic factors [
69], such as the increased frequency of RAG-mediated DSBs at the
Igh or
Igl locus in the context of secondary V(D)J recombination. In this regard, these results are consistent with our previous findings that a small percentage of peripheral B cells harbor RAG-dependent
Igλ breaks/translocations in the absence of
Xrcc4 [
15]. Thus, our conclusion is further corroborated that mature B lymphocytes can undergo secondary V(D)J recombination, which may contribute to mature B cell lymphomagenesis.
Our data reveal that
Trp53 deficiency is essential to cause B cell lymphomas; however,
Trp53 deficiency per se does not increase the level of DSBs markedly. Thus, we propose that
Trp53 deficiency enhances the tolerance threshold of B cells for genomic instability induced by DNA repair deficiency in our model, thereby predisposing to lymphomagenesis. Consistent with our hypothesis, it has been shown that, in response to DSBs, p53 is phosphorylated and activated by ATM [
70], then monitors DSBs in the context of G1 checkpoints, and signals arrest and/or apoptosis [
71].
Trp53 deficient mice usually succumb to thymic lymphomas that are aneuploid but lack translocations [
72‐
75]. Of note, CD21cre-mediated deletion of
Trp53 in peripheral B cells results in the development of mature B cell lymphomas (IgM
+) that lack recurrent clonal translocations involving
Ig or
c-myc loci [
76]. Overall, these findings support our hypothesis that
Trp53 deficiency enables B cells to tolerate genomic instability. Furthermore, we propose that the regulation of genomic instability tolerance is more p53-dependent in B cells than in other cell lineages. This notion is supported by the findings that NHEJ/p53 germline deficient mice developed only pro-B cell lymphomas [
39,
43]. Thus, our unique mouse model may facilitate the discovery of critical components of p53-mediated effector cascades that regulate genomic instability tolerance. Furthermore, we were able to establish cell lines from our lymphoma model (data not shown), which would facilitate subsequent studies. Addressing these fundamental questions potentially identifies targets that specifically attack cancer cells with unstable genomes, while leaving genetically stable normal cells unaffected.
With regard to the potential of our model in clinical applications, such as biomarkers for diagnosis and therapy [
77], we suggest that our unique model might potentially provide novel insights into the biomarker development in predicting the onset of the B cell lymphomas, given that this lymphoma model has a relatively long latency and low penetrance. In addition, novel therapies have been developed rapidly to treat B cell lymphomas or CLL, for example, Ibrutinib and new agents are effective for
TP53 mutant lymphoma cells; thus, there is the potential of clinical applications of our lymphoma model for testing new agents [
78‐
80]. Mechanistically, it would be of interest to elucidate which signaling pathway is required for the survival of these lymphoma cells.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JHW and ZC designed the study and wrote the paper. JHW, ZC, and SSV established the mouse cohorts, monitored the survival, and collected the tumor samples for NGS and FACS analysis. JHW, ZC, MTE, and SSV contributed to the metaphase FISH analysis of primary B cells and lymphoma samples. KG, SL, and KJ analyzed the NGS sequencing data. KG performed the Circo plot analysis. SL employed the IGV software to identify the translocation locations. JHW, MTE, and MR manually aligned the translocation junction sequences. JHW and MTE performed the γH2AX foci staining. MDE provided the technical assistance for FISH acquisition, analysis, and sequence alignment. All authors read and approved the final manuscript.